共 115 条
[1]
Savarese G(2017)Global public health burden of heart failure Card Fail Rev 3 7-11
[2]
Lund LH(2015)The impact of worsening heart failure in the United States Heart Fail Clin 11 603-614
[3]
Cooper LB(2016)2016 ACC/AHA/HFSA focused update on new pharmacological therapy for heart failure: an update of the 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America J Cardiac Fail 22 659-669
[4]
DeVore AD(2013)ACCF/HRS/AHA/ASE/HFSA/SCAI/SCCT/SCMR 2013 Appropriate Use Criteria for Implantable Cardioverter-Defibrillators and Cardiac Resynchronization Therapy: A Report of the American College of Cardiology Foundation Appropriate Use Criteria Task Force, Heart Rhythm Society, American Heart Association, American Society of Echocardiography, Heart Failure Society of America, Society for Cardiovascular Angiography and Interventions, Society of Cardiovascular Computed Tomography, and Society f
[5]
Michael FG(2017)Baroreflex activation therapy: a new approach to the management of advanced heart failure with reduced ejection fraction J Cardiovasc Med 18 641-649
[6]
Yancy CW(2020)Baroreflex activation therapy in patients with heart failure with reduced ejection fraction J Am Coll Cardiol 76 1-13
[7]
Jessup M(2005)How well does B-type natriuretic peptide predict death and cardiac events in patients with heart failure: systematic review BMJ (Clinical research ed) 330 625-184
[8]
Bozkurt B(2002)Cardiac transplantation Heart 87 177-1038
[9]
Butler J(2018)National trends in prescription drug expenditures and projections for 2018 Am J Health-Syst Pharm 75 1023-2436
[10]
Casey DE(2016)Prognostic implications of changes in N-terminal pro-B-type natriuretic peptide in patients with heart failure J Am Coll Cardiol 68 2425-251